STERIS Announces Leadership Succession Plan
STERIS plc (NYSE: STE) announced the planned resignation of CEO Walt Rosebrough, effective July 29, 2021. Chief Operating Officer Dan Carestio will succeed him. Rosebrough will transition to a role as CEO Emeritus and Senior Advisor for two years. Under Rosebrough's leadership, STERIS achieved significant milestones, including tripling revenue and completing nearly 50 acquisitions, resulting in a market capitalization increase of over $14 billion. The Board expressed confidence in Carestio's leadership skills and successful integration of various business segments.
- Rosebrough's tenure saw revenue growth tripled.
- Market capitalization increased by over $14 billion.
- Dan Carestio's extensive experience within the company.
- Successful integration of multiple business segments.
- None.
- Walt Rosebrough to step down as CEO at the upcoming Annual General Meeting
- Chief Operating Officer, Dan Carestio, to succeed as President and CEO
DUBLIN, IRELAND, Feb. 03, 2021 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that Walt Rosebrough, President and CEO, has announced his intention to step down on July 29, 2021, in conjunction with the company’s Annual General Meeting. Mr. Rosebrough will remain as CEO Emeritus and Senior Advisor to STERIS’s leadership and Board for the next two years.
STERIS’s Board of Directors has unanimously appointed Dan Carestio, currently Chief Operating Officer (COO), to the Board of Directors as of January 29, 2021 and Mr. Carestio will succeed Mr. Rosebrough as President and CEO, effective July 29, 2021. The board intends to include Mr. Carestio on the slate of Directors for election at the upcoming Annual General Meeting, and Mr. Rosebrough has advised the Board that he does not intend to stand for re-election.
“I believe that STERIS is stronger and better positioned than ever and has a very talented overall leadership team in place to continue to drive forward,” said Walt Rosebrough, President and CEO. “Dan has been with STERIS over twenty years with progressively increasing responsibilities in marketing, sales, and general management. He drove our improvements in Life Sciences and Applied Sterilization Technologies (AST) segments the past decade. He led the successful integration of the Synergy Health AST business, took on the additional leadership of our Healthcare IPT business when that leader retired, and finally became responsible for all our operations as COO in 2018. The success of all three of our business segments since he became COO is a testament to Dan and the STERIS leadership team. I am extremely confident that Dan is the right person to lead STERIS into the future.”
“This announcement follows a well-planned and thoughtful succession process, which prioritizes developing leaders from within the Company,” said Dr. Mohsen Sohi, Chairman of the Board. “Dan has a long history of demonstrating his ability to lead and drive results, and the Board has full confidence in him as the next CEO for STERIS. We are fortunate to have had Walt’s leadership for well over a decade, through some of the most challenging times in STERIS’s history. During Walt’s tenure, we have grown revenue three-fold, completed close to fifty acquisitions, added more than 8,000 people to our workforce and grown shareholder value nearly 10 times, adding over
About STERIS
STERIS’s MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. For more information, visit www.steris.com.
Investor Contact:
Julie Winter, Vice President, Investor Relations and Corporate Communications
Julie_Winter@steris.com
+1 440 392 7245
Media Contact:
Stephen Norton, Senior Director, Corporate Communications
Stephen_Norton@steris.com
+1 440 392 7482
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This press release may contain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements speak only as to the date the statement is made and may be identified by the use of forward-looking terms such as “may,” “will,” “expects,” “believes,” “anticipates,” “plans,” “estimates,” “projects,” “targets,” “forecasts,” “outlook,” “impact,” “potential,” “confidence,” “improve,” “optimistic,” “deliver,” “orders,” “backlog,” “comfortable,” “trend”, and “seeks,” or the negative of such terms or other variations on such terms or comparable terminology. These forward-looking statements are based on current expectations, estimates or forecasts about our businesses, the industries in which we operate and current beliefs and assumptions of management and are subject to uncertainty and changes in circumstances. Investors should understand that these statements are not guarantees of performance or results. Many important factors could affect actual financial results and cause them to vary materially from the expectations contained in the forward-looking statements. No assurances can be provided as to any result or the timing of any outcome regarding matters described in STERIS’s or Cantel’s securities filings or otherwise with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, cost reductions, business strategies, earnings or revenue trends or future financial results. Unless legally required, we do not undertake to update or revise any forward-looking statements even if events make clear that any projected results, express or implied, will not be realized. These risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include, without limitation:
• the failure to obtain Cantel stockholder approval of the proposed transaction;
• the possibility that the closing conditions to the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant a necessary regulatory approval and any conditions imposed on the combined entity in connection with consummation of the proposed transaction;
• delay in closing the proposed transaction or the possibility of non-consummation of the proposed transaction;
• the risk that the cost savings and any other synergies from the proposed transaction may not be fully realized or may take longer to realize than expected, including that the proposed transaction may not be accretive within the expected timeframe or to the extent anticipated;
• the occurrence of any event that could give rise to termination of the merger agreement;
• the risk that shareholder/stockholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transactions or result in significant costs of defense, indemnification and liability;
• risks related to the disruption of the proposed transaction to STERIS, Cantel and our respective managements;
• risks relating to the value of the STERIS shares to be issued in the transaction;
• the effect of announcement of the proposed transaction on our ability to retain and hire key personnel and maintain relationships with customers, suppliers and other third parties;
• the impact of the COVID-19 pandemic on STERIS’s or Cantel’s operations, performance, results, prospects, or value;
• STERIS’s ability to achieve the expected benefits regarding the accounting and tax treatments of the redomiciliation to Ireland (“Redomiciliation”);
• operating costs, Customer loss and business disruption (including, without limitation, difficulties in maintaining relationships with employees, Customers, clients or suppliers) being greater than expected following the Redomiciliation;
• STERIS’s ability to meet expectations regarding the accounting and tax treatment of the Tax Cuts and Jobs Act (“TCJA”) or the possibility that anticipated benefits resulting from the TCJA will be less than estimated;
• changes in tax laws or interpretations that could increase our consolidated tax liabilities, including changes in tax laws that would result in STERIS being treated as a domestic corporation for United States federal tax purposes;
• the potential for increased pressure on pricing or costs that leads to erosion of profit margins;
• the possibility that market demand will not develop for new technologies, products or applications or services, or business initiatives will take longer, cost more or produce lower benefits than anticipated;
• the possibility that application of or compliance with laws, court rulings, certifications, regulations, regulatory actions, including without limitation any of the same relating to FDA, EPA or other regulatory authorities, government investigations, the outcome of any pending or threatened FDA, EPA or other regulatory warning notices, actions, requests, inspections or submissions, or other requirements or standards may delay, limit or prevent new product or service introductions, affect the production, supply and/or marketing of existing products or services or otherwise affect STERIS’s or Cantel’s performance, results, prospects or value;
• the potential of international unrest, economic downturn or effects of currencies, tax assessments, tariffs and/or other trade barriers, adjustments or anticipated rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs;
• the possibility of reduced demand, or reductions in the rate of growth in demand, for STERIS’s or Cantel’s products and services;
• the possibility of delays in receipt of orders, order cancellations, or delays in the manufacture or shipment of ordered products or in the provision of services;
• the possibility that anticipated growth, cost savings, new product acceptance, performance or approvals, or other results may not be achieved, or that transition, labor, competition, timing, execution, regulatory, governmental, or other issues or risks associated with STERIS’s and Cantel’s businesses, industry or initiatives including, without limitation, those matters described in STERIS’s and Cantel’s respective Annual Reports on Form 10-K for the year ended March 31, 2020 and July 31, 2020, respectively, and other securities filings, may adversely impact STERIS’s and/or Cantel’s performance, results, prospects or value;
• the impact on STERIS and its operations, or tax liabilities, of Brexit or the exit of other member countries from the EU, and STERIS’s ability to respond to such impacts;
• the impact on STERIS, Cantel and their respective operations of any legislation, regulations or orders, including but not limited to any new trade or tax legislation, regulations or orders, that may be implemented by the U.S. administration or Congress, or of any responses thereto;
• the possibility that anticipated financial results or benefits of recent acquisitions, including the acquisition of Key Surgical, or of STERIS’s restructuring efforts, or of recent divestitures, or of restructuring plans will not be realized or will be other than anticipated;
• the effects of contractions in credit availability, as well as the ability of STERIS’s and Cantel’s Customers and suppliers to adequately access the credit markets when needed;
• STERIS’s ability to complete the acquisition of Cantel, including the fulfillment of closing conditions and obtaining financing, on terms satisfactory to STERIS or at all; and
• other risks described in STERIS’s and Cantel’s respective most recent Annual Reports on Form 10-K and other reports filed with the Securities and Exchange Commission.
Investors are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by applicable law. This cautionary statement is applicable to all forward-looking statements contained herein.
FAQ
When will Walt Rosebrough step down as CEO of STERIS?
Who will succeed Walt Rosebrough as CEO of STERIS?
What achievements did STERIS have under Walt Rosebrough's leadership?
What position will Walt Rosebrough hold after stepping down?
How long has Dan Carestio been with STERIS?
